Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

EGFR-mutant non-small cell lung cancer are often resistant to EGFR tyrosine kinase inhibitor treatment. In this study, the authors show that resistant tumors display high Akt activation and that a combined treatment with AKT inhibitors causes synergistic tumour growth inhibition in vitro and in vivo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kirstine Jacobsen, Jordi Bertran-Alamillo, Miguel Angel Molina, Cristina Teixidó, Niki Karachaliou, Martin Haar Pedersen, Josep Castellví, Mónica Garzón, Carles Codony-Servat, Jordi Codony-Servat, Ana Giménez-Capitán, Ana Drozdowskyj, Santiago Viteri, Martin R. Larsen, Ulrik Lassen, Enriqueta Felip, Trever G. Bivona, Henrik J. Ditzel, Rafael Rosell
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/a117794eb5cd402d8bf7134ca915cc6e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a117794eb5cd402d8bf7134ca915cc6e
record_format	dspace
spelling	oai:doaj.org-article:a117794eb5cd402d8bf7134ca915cc6e2021-12-02T15:38:54ZConvergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer10.1038/s41467-017-00450-62041-1723https://doaj.org/article/a117794eb5cd402d8bf7134ca915cc6e2017-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-017-00450-6https://doaj.org/toc/2041-1723EGFR-mutant non-small cell lung cancer are often resistant to EGFR tyrosine kinase inhibitor treatment. In this study, the authors show that resistant tumors display high Akt activation and that a combined treatment with AKT inhibitors causes synergistic tumour growth inhibition in vitro and in vivo.Kirstine JacobsenJordi Bertran-AlamilloMiguel Angel MolinaCristina TeixidóNiki KarachaliouMartin Haar PedersenJosep CastellvíMónica GarzónCarles Codony-ServatJordi Codony-ServatAna Giménez-CapitánAna DrozdowskyjSantiago ViteriMartin R. LarsenUlrik LassenEnriqueta FelipTrever G. BivonaHenrik J. DitzelRafael RosellNature PortfolioarticleScienceQENNature Communications, Vol 8, Iss 1, Pp 1-14 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Kirstine Jacobsen Jordi Bertran-Alamillo Miguel Angel Molina Cristina Teixidó Niki Karachaliou Martin Haar Pedersen Josep Castellví Mónica Garzón Carles Codony-Servat Jordi Codony-Servat Ana Giménez-Capitán Ana Drozdowskyj Santiago Viteri Martin R. Larsen Ulrik Lassen Enriqueta Felip Trever G. Bivona Henrik J. Ditzel Rafael Rosell Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
description	EGFR-mutant non-small cell lung cancer are often resistant to EGFR tyrosine kinase inhibitor treatment. In this study, the authors show that resistant tumors display high Akt activation and that a combined treatment with AKT inhibitors causes synergistic tumour growth inhibition in vitro and in vivo.
format	article
author	Kirstine Jacobsen Jordi Bertran-Alamillo Miguel Angel Molina Cristina Teixidó Niki Karachaliou Martin Haar Pedersen Josep Castellví Mónica Garzón Carles Codony-Servat Jordi Codony-Servat Ana Giménez-Capitán Ana Drozdowskyj Santiago Viteri Martin R. Larsen Ulrik Lassen Enriqueta Felip Trever G. Bivona Henrik J. Ditzel Rafael Rosell
author_facet	Kirstine Jacobsen Jordi Bertran-Alamillo Miguel Angel Molina Cristina Teixidó Niki Karachaliou Martin Haar Pedersen Josep Castellví Mónica Garzón Carles Codony-Servat Jordi Codony-Servat Ana Giménez-Capitán Ana Drozdowskyj Santiago Viteri Martin R. Larsen Ulrik Lassen Enriqueta Felip Trever G. Bivona Henrik J. Ditzel Rafael Rosell
author_sort	Kirstine Jacobsen
title	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
title_short	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
title_full	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
title_fullStr	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
title_full_unstemmed	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
title_sort	convergent akt activation drives acquired egfr inhibitor resistance in lung cancer
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/a117794eb5cd402d8bf7134ca915cc6e
work_keys_str_mv	AT kirstinejacobsen convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT jordibertranalamillo convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT miguelangelmolina convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT cristinateixido convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT nikikarachaliou convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT martinhaarpedersen convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT josepcastellvi convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT monicagarzon convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT carlescodonyservat convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT jordicodonyservat convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT anagimenezcapitan convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT anadrozdowskyj convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT santiagoviteri convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT martinrlarsen convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT ulriklassen convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT enriquetafelip convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT trevergbivona convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT henrikjditzel convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer AT rafaelrosell convergentaktactivationdrivesacquiredegfrinhibitorresistanceinlungcancer
_version_	1718386064849108992

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

Ejemplares similares